New York, February 3, 2026, 18:04 EST — Trading after the close.
- Eli Lilly shares dropped 3.9% on Tuesday, following a wider sell-off in obesity-drug stocks.
- Novo Nordisk’s forecast for 2026 reignited concerns over pricing pressure in GLP-1 weight-loss medications.
- Lilly will release its quarterly results on Wednesday.
Eli Lilly and Company (LLY) shares dropped 3.9%, closing at $1,003.46 on Tuesday, then held steady in after-hours trading. Novo Nordisk’s U.S.-listed shares plunged 14%, after it forecast a steeper sales decline than expected for 2026, weighing on the obesity-drug sector. Pfizer also slipped following new weight-loss drug data. “Novo’s showing there’s a market for oral options,” noted Citizens analyst Jonathan Wolleben. (Reuters)
This move is crucial for Lilly, as its stock has become emblematic of the weight-loss surge: maintain volume growth without sacrificing too much on price. GLP-1 drugs, which imitate gut-hormone signals to suppress appetite and reduce blood sugar, are now confronting a more challenging financial equation.
Analysts are scaling back long-term obesity market forecasts as U.S. prices drop and competition intensifies. Jefferies analyst Michael Leuchten bluntly stated, “That $150 billion pie is gone.” HSBC’s Rajesh Kumar noted the sharp price cuts, saying, “You certainly need volumes to pick up a lot,” after Novo and Lilly started selling online for $149 to $299 a month under a deal with the Trump administration. LSEG data show analysts still expect Lilly’s revenue to climb over 21% and adjusted earnings to jump more than 40% in 2026 compared to 2025 estimates. (Reuters)
Lilly’s Zepbound shot goes toe-to-toe with Novo’s Wegovy, quickly turning into a key indicator for the whole weight-loss sector. Investors are keenly tracking if quicker patient uptake can balance out the impact of price cuts and the move toward direct-to-consumer sales.
Novo CEO Mike Doustdar warned the company will encounter “pricing headwinds in an increasingly competitive market” come 2026. That caution sent ripples through U.S.-listed obesity stocks. Lilly’s Zepbound has now surpassed Wegovy in U.S. prescriptions, intensifying the battle for market share as both frontrunners slash prices. (Reuters)
Lilly will release its fourth-quarter 2025 financial results on Feb. 4, with a conference call scheduled for 10 a.m. Eastern time. (Nasdaq)
Guidance is shaping up as the key moment. Traders will zero in on management’s take on demand, supply expansion, and rebates—and whether price cuts are turning into the norm instead of the outlier.
The obesity trade is crowded and ruthless. If Lilly hints at quicker price drops, slower patient gains, or steeper discounts to maintain access, the stock might remain under pressure despite steady top-line growth.
Wednesday brings Lilly’s report and outlook, with investors eager for clues on whether the weight-loss market is shifting toward a lower-price, higher-volume dynamic.
